Posts Tagged 'transvaginal mesh'

Blog: $1.2b J&J fine for Risperdal deceptive marketing likely to cause further problems

A post on stock market information Website Seeking Alpha says Johnson & Johnson will likely deal with significant public backlash going forward. An Arkansas jury recently concluded that the company used deceptive tactics to market antipsychotic drug Risperdal, which included hiding or minimizing the drug’s risks. A judge then issued a $1.2 billion fine.

The post says the fine leveled against Johnson and Johnson and subsidiary Janssen Pharmaceuticals is the largest ...

continue reading...

FDA defends medical device approval process

An internal document from the U.S. Food and Drug Administration defends the agency’s rejection of European standards for approving medical devices, according to a report in the Minneapolis-St. Paul Star Tribune.

The FDA document amounts to the agency’s defense of its own practices, and describes 12 classes of allegedly “unsafe and ineffective” high-risk medical devices approved for sale in Europe but not the United States.

According to the Star Tribune, the United ...

continue reading...

Doctor: No advantage to dangerous implant

In testimony before the U.S. Food and Drug Administration, Dr. Michael Carome called for a ban on all vaginal mesh products, on the grounds that they have no advantages over other forms of treatment, yet cause a host of severe health problems.

Mesh implants are used to treat urinary incontinence and pelvic organ prolapse – a condition that results when weakened muscles provide inadequate support for internal ...

continue reading...

J&J reports profit increase, despite troubles

Johnson & Johnson reports that its first-quarter profits increased by 12.5 percent, Bloomberg reports. That increase came despite the company’s problems with nearly 30 recalls for a number of nonprescription and prescription medicines, as well as medical devices.

That 12.5-percent increase came about primarily because of lower spending on research, sales and administration and a boost from selling rights to a drug, the report said.

According to the report, Johnson & ...

continue reading...

Jury says Johnson & Johnson improperly marketed Risperdal

A jury in Arkansas ruled that Johnson & Johnson officials used deceptive tactics to market antipsychotic drug Risperdal, misleading doctors about the drug’s risks and improperly marketing it for unapproved uses, Bloomberg reports.

The decision in Arkansas marks the third such jury verdict against Johnson & Johnson over allegations that the pharmaceutical giant concealed Risperdal’s risks and tricked Medicaid regulators into paying more than they should have for the medication.

Juries also decided against the company in Louisiana and South Carolina.

A total ...

continue reading...

New J&J CEO involved in previous recall

A Newark Star-Ledger profile of Alex Gorsky, the new CEO of Johnson & Johnson, describes him as “the go-to man” during the company’s 1998 recall of Hismanal, an antihistamine that proved to have dangerous cardiovascular side effects.

Gorsky has succeeded previous chief executive officer William Weldon, who stepped down after a disastrous series of recalls. But the Star-Ledger mentions that some industry observers are questioning whether Gorsky played a part in marketing a hip implant that has generated thousands of lawsuits ...

continue reading...
Page 32 of 35 «...10203031323334...»